Evidence map›Paper›PMID 33772636›Full record

Observational studyJournal of neurology2021

The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.

Marta Torres-Ferrús, Victor J Gallardo, Alicia Alpuente, Edoardo Caronna, Eulalia Gine-Cipres, Patricia Pozo-Rosich

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 4 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marta Torres-FerrúsHeadache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, 119-129 Passeig de la Vall d'Hebron, 08035, Barcelona, Spain.
Victor J GallardoHeadache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Alicia AlpuenteHeadache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, 119-129 Passeig de la Vall d'Hebron, 08035, Barcelona, Spain.
Edoardo CaronnaHeadache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Eulalia Gine-CipresHeadache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, 119-129 Passeig de la Vall d'Hebron, 08035, Barcelona, Spain.
Patricia Pozo-RosichHeadache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, 119-129 Passeig de la Vall d'Hebron, 08035, Barcelona, Spain. ppozo@vhebron.net.
Universitat Autònoma de Barcelona · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the frequency and headache-related impact response to monoclonal antibodies against calcitonin gene-related peptide (CGRP) in a clinical sample of refractory migraine patients.

methodsWe included migraine patients with ≥ 8 headache days/month that had failed at least three preventive medications. Demographic, medical and migraine history were collected. Patients completed an electronic headache diary including headache days/month, migraine days/month, headache pain intensity (0-3 numerical scale), use of analgesics and completed Patient-Reported Outcome questionnaires at baseline and after 12 weeks. Patients were classified into ≥ 50%, ≥ 75% and 100% responders according to the improvement in frequency.

resultsWe included 155 patients (109 erenumab and 46 galcanezumab). After 12 weeks, headache frequency decreased - 9.1 headache days/month and - 8.5 migraine days/month from baseline. A 39.5% had a ≥ 50% headache days/month reduction and a 51.6% ≥ 50% migraine days/month reduction. In the ≥ 50% migraine days/month-responders group, frequency reduction was - 13,9 migraine days/month from baseline and showed clear improvements for all patient-reported outcomes. A 14.2% and 26.5% had a ≥ 75% response in headache and migraine days/month, respectively, and 11.0% showed a 100% migraine days/month reduction. Patients who were not on other preventive medications had less severe disability and higher ratio of migraine over headache days/month were more likely of being a ≥ 50% migraine days/month-responder. We did not record any severe adverse events, being the most common constipation (20.0%), fatigue (7.1%) and a transient increase in blood pressure (5.2%).

conclusionsIn real-world clinical practice, monoclonal antibodies against CGRP proved to be effective treatments in resistant migraine patients.

Indexed as

Calcitonin Gene-Related PeptideMigraine DisordersAntibodies, MonoclonalCalcitoninCalcitonin Gene-Related Peptide Receptor AntagonistsHumansTreatment OutcomeAntibodies, MonoclonalCalcitoninCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsCalcitonin gene-related peptideErenumabGalcanezumabMigraineMigraine preventionMonoclonal antibodiesReal-world

Identifiers

PMID33772636
OpenAlexW3139684698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.